Immutep and Monash University Secure $652k ARC Grant for LAG 3 Research
Get your Free Report on Top 5 ASX stocks for 2025
Clinical stage biotech Immutep Limited (ASX: IMM) announced on 14 October 2026 that Monash University has been awarded a three year $652,248 grant under the Australian Research Council Linkage Projects scheme to support ongoing joint research into Lymphocyte Activation Gene 3.
The grant funds a project titled "A structural investigation into Lymphocyte activation gene 3" which is led by Professor Jamie Rossjohn at Monash’s Biomedicine Discovery Institute. The team will examine LAG 3’s interactions with MHC Class II and its activity in the immunological synapse using structural biology, cellular immunology and imaging techniques.
The research will evaluate IMP761 which is Immutep’s agonist antibody candidate and focus on ligand binding and immune regulation. Immutep plans to contribute expertise, LAG 3 specific reagents and co funding from its current research budget with these contributions not considered financially material.
The company has highlighted that the ARC funding will expand fundamental LAG 3 knowledge and strengthen scientific foundations for next generation immunotherapies. Management also noted that coupling academic structural biology with industry led checkpoint expertise will accelerate therapeutic innovations across cancer and autoimmune diseases.
This latest grant extends a research alliance which has been active since 2017. The partnership has previously generated the first crystal structure of the human LAG 3/MHC Class II complex that was published in Science Immunology in December 2024 which provided key structural insights into receptor ligand engagement.
(Source: Company Announcements)
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
Feature News
Checkout Our Recommendation for free - 7 days free trial
Start Free TrialRecent News
PainChek Expands US Footprint to 23 Communities Un..
First Au Secures Binding Deal to Acquire Ida Valle..
Solara Minerals discovers high-grade gold at Myrna..
Sea Forest signs a major distribution deal with Te..
SKS Technologies secures additional MEL2 data cent..